Posted by Michael Wonder on 22 Feb 2023
Calquence tablet formulation approved in the EU for patients with chronic lymphocytic leukaemia
22 February 2023 - Approval based on ELEVATE-PLUS trials which showed bioequivalence and consistent dosing versus current capsule.
AstraZeneca’s tablet formulation of Calquence (acalabrutinib) has been approved in the EU for the treatment of adult patients with chronic lymphocytic leukaemia.
